未登录

L

Leo Thomas

Physikalisch-Technische Bundesanstalt

H指数:22

被引数:2,664

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Active learning-based optimization of variance reduction of Monte Carlo simulations: a feasibility study for the case of nanodosimetry around a gold nanoparticle

基于主动学习的蒙特卡罗模拟方差缩减优化：金纳米粒子周围纳米剂量学案例的可行性研究

Physica Scripta

IF2.6

2026-04-300

OAAI

Radial dependence of ionization clustering around a gold nanoparticle irradiated by X-rays under charged particle equilibrium

PHYSICS IN MEDICINE AND BIOLOGY

IF3.4

2024-09-134

OA

The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection

DIABETES OBESITY & METABOLISM

IF5.7

2024-04-014

OA

BI-Y, an Neuropilin-1 Antagonist, Enhances Revascularization and Prevents Vascular Endothelial Growth Factor-A Induced Retinal Hyperpermeability in Rodent Models of RetinopathiesS

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

IF3.8

2023-06-010

OAAI

BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy

MOLECULAR METABOLISM

IF6.6

2022-12-0168

OAAI

Efficacy of an Anti-Semaphorin 3A Neutralizing Antibody in a Male Experimental Retinal Vein Occlusion Mouse Model

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

IF4.7

2022-07-134

OAAI

Inhibition of acetyl-CoA carboxylase 2 enhances skeletal muscle fatty acid oxidation and improves whole-body glucose homeostasis in db/db mice

IF10.2

2012-04-2534

OAAI

Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats

DIABETES OBESITY & METABOLISM

IF5.7

2011-11-1358

PREAI

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

DIABETES OBESITY & METABOLISM

IF5.7

2011-11-13537

PREAI

Chronic Treatment with the Dipeptidyl Peptidase-4 Inhibitor BI 1356 [(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] Increases Basal Glucagon-Like Peptide-1 and Improves Glycemic Control in Diabetic Rodent Models

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

IF3.8

2009-02-0163

PREAI

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

IF3.8

2008-04-01323

PREAI

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2007-12-01313

PREAI